title: [Hepatitis C virus variability and interferon-mediated pathway inhibition].
abstract: The most important aim of this study was to describe the hypothetical relationship between the PePHD region variability (related to the synthesis of a cellular enzyme pseudosubstrate) of the hepatitis C virus and the response of patients to interferon therapy. This interaction could be a determining factor in the antiviral effect of interferon. All samples (from 24 patients with chronic hepatitis C infection) were analyzed using a previously described method based on RT-PCR and nested PCR mediated by single-strand conformation polymorphism assay (SSCP). The patients were divided into three groups with respect to the response to therapy: 8 patients with sustained response, 8 patients with transient response and 8 nonresponders. In all samples a low genetic heterogeneity pattern was detected, which was independent of other factors involved in the lack of response to treatment, such as age, sex or viral genotype. This genetic homogeneity is an indirect indication of the importance of the region on viral persistence. However, more studies are needed to evaluate the real role of this sequence on the interaction between cells and the virus.
authors.affiliation: Dpto. de Inmunologia, Microbiologia y Parasitologia, Facultad de Medicina y Odontologia, Universidad del Pais Vasco/Euskal Herriko Unibertsitatea, Bilbao, Spain.
authors.forename: B
authors.initials: B
authors.lastname: Fernández
authors.forename: M
authors.initials: M
authors.lastname: Basaras
authors.forename: S
authors.initials: S
authors.lastname: Blanco
authors.forename: S
authors.initials: S
authors.lastname: Sánchez
authors.forename: E
authors.initials: E
authors.lastname: Arrese
authors.forename: B
authors.initials: B
authors.lastname: de las Heras
authors.forename: R
authors.initials: R
authors.lastname: Cisterna
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D014644:Genetic Variation; D016174:Hepacivirus / Q000187:drug effects / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology*; D006801:Humans; D016898:Interferon-alpha / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha